Paik PK, Felip E, Veillon R, et al. - Among patients with advanced or metastatic non–small-cell lung cancer (NSCLC) and a confirmed MET exon 14 skipping mutation, researchers tested the effectiveness and safety of tepotinib, a highly selective MET inhibitor. Tepotinib (at a dose of 500 mg) was administered once daily in 152 patients in this open-label, phase 2 study. Objective response via independent review in 99 patients followed for at least 9 months was the primary endpoint. Treatment with tepotinib resulted in a partial response in nearly half the patients with advanced NSCLC and a confirmed MET exon 14 skipping mutation. The main toxic impact of grade 3 or higher was peripheral edema.